Real-time Stock quotes, portfolio, LIVE TV and more.
May 10, 2012, 05.53 PM IST
Cadila Healthcare is expected to report a decline of 4% year-on-year in its profit after tax of Rs 171.7 crore for the fourth quarter of FY12, according to CNBC-TV18 poll.
Revenues are seen going up by 13.7% to Rs 1,379 crore from Rs 1,213 crore year-on-year.
EBITDA is likely to go up by 18% to Rs 269 crore from Rs 227.8 crore during the same period.
Operating profit margin is expected to be at 19.5% versus 18.8% YoY.
In Q3FY12, domestic formulation business (contributed 34%) grew by 18% to Rs 469 crore due to acquisition of Biochem. Excluding Biochem growth was 12% YoY
Watch out for Consumer business (under Zydus Wellness), which recorded a significant slowdown in 9MFY12 (0% growth YoY for 9MFY12 and 12% YoY decline in Q3FY12 due to rising competition.
Consumer business (contributed 6%) de-grew by 12% due to increase in competitive pressures from MNCs on key brands Sugar Free, EverYuth and Nutralite
US growth is expected to be flat QoQ
Do not expect a one of income from Nycomed JV like the last Q where there was a one off sale of Rs 15 crore
Tags: Cadila Healthcare
May 22 2013, 13:11
- in MARKET OUTLOOK
May 22 2013, 10:44
- in Economy